Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics
Biocon Founder And Chairperson Discusses Integration, Pipeline And New Target Markets
Executive Summary
As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.
You may also be interested in...
Triple Threat: EMA Endorses Three First-Time Biosimilars
At an eventful European Medicines Agency committee meeting in July, three biosimilars from Biocon, Sandoz and Fresenius Kabi have become the first for each respective molecule – aflibercept, natalizumab and tocilizumab – to gain the endorsement of the CHMP.
Biocon Biologics Integrates Viatris Business As It Introduces Adalimumab
In a busy couple of weeks for Biocon’s biosimilars unit, the firm has completed the “first wave” of integration for the business it acquired from Viatris, while also launching its US adalimumab biosimilar amid heavy competition.
Biocon Closes $3bn Deal For Viatris Biosimilars
Biocon has achieved a milestone after its Biocon Biologics subsidiary closed its $3bn deal to acquire the biosimilars business of longtime partner Viatris, in what management described as a “historic inflection point” for the Indian player.